Avanos Medical Appoints SVP Scott Galovan As SVP, CFO Effective Aug. 1, 2025

Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025.

 

Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A roles for Newell Brands, Equity Pacific Partners, and Intel Capital.

As CFO, Galovan will oversee the company's global finance, treasury, tax, corporate development, investor relations, and accounting groups, as well as its Enterprise Program Management Office. He will report directly to David Pacitti, Avanos chief executive officer.

"Scott brings a growth-oriented mindset to the CFO role, which will be critical as we look to build on the significant progress we've made with our transformation efforts," said Pacitti. "His ability to drive strategic partnerships, coupled with his deep understanding of market dynamics, will help to shape our next chapter, enhance our long-term planning, and maintain a sharp focus on shareholder value."

Galovan earned a bachelor's degree from BYU and a master's of business administration from the University of California at Los Angeles, where he was a Venture Fellow.

The Company also announced the appointment of Pacitti as a member of its board of directors, effective Aug. 1, 2025.